GenomeDx’s Decipher GRID Assesses Novel Biomarker for Prostate Cancer Outcome, Validates Decipher Test

GenomeDx’s Decipher GRID Assesses Novel Biomarker for Prostate Cancer Outcome, Validates Decipher Test
GenomeDx Biosciences, a genomic information company that develops and commercializes clinical tests using great amounts of genomic data, has announced the results of two separate studies that confirm the potential and power of its Decipher Genomic Resource Information Database (Decipher GRID) to improve disease management and predict patient outcomes. The results were presented by Dr

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *